Macugen blocks the effects of Vascular Endothelial Growth Factor, (VEGF). VEGF is implicated in the development and progression of wet macular degeneration, diabetic retinopathy, and macular edema. VEGF not only promotes the growth of new abnormal blood vessels but increases the permeability of existing vessels leading to leakage. By blocking VEGF, Macugen can, in some cases, improve outcomes in patients with a broad variety of retinal and macular diseases. The physicians at Saskatoon Eye Surgeons have extensive experience with the use of Macugen. While, newer agents such as Lucentis and Avastin, have been developed since the approval of Macugens, it continues to have a role in the management of a variety of retinal and macular conditions.